HealthNews Pulse
Experimental AstraZeneca Drug Cuts COPD Flare-Ups in Late-Stage Trials
AstraZeneca's experimental monoclonal antibody tozorakimab reduced moderate-to-severe COPD exacerbations by roughly 29% to 34% in two late-stage studi…
Read the full pulseContinue in Briflio to read, react, comment, and share.
Sources